10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.
23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.
Abbott is engaged in pharmaceuticals and manufacturing healthcare products. It developed the first HIV blood-screening test. Its product portfolio includes Norvir, a treatment for HIV; Synthroid, a synthetic thyroid hormone; Depakote, an anticonvulsant drug; and Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more. Its medical tests and diagnostic instrument systems are manufactured for usage in hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, and more. Abbott also operates its product manufacturing segment known as Abbott Point-of-Care. It manufactures diagnostic products for blood analysis. It also provides cardiac assays to the emergency room. It currently has 90,000 employees and operates in over 130 countries. Abbott was established in 1888 by Chicago physician Wallace Calvin Abbott. It is based in Abbott Park, North Chicago, Illinois.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.
AbSci is a synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process. They custom engineer E. coli to create novel complex biologics in their full length format while simultaneously developing production cell lines. The company is deploying cutting-edge deep learning artificial intelligence to inform their designs, and every day we succeed in achieving things others have dismissed as impossible.
Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores the Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while reatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan. AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1 Expression System for mammalian production. Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time. Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.
Agena Bioscience is a molecular diagnostics company that develops and markets genetic reagents and analysis systems. Agena Bioscience's MassARRAY System is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used in a range of clinical diagnostic and research fields such as infectious diseases, cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. The company's genetic platform delivers timely, accurate, and easy-to-interpret results, to improve decision-making and laboratory economics.
Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.
Aiforia Technologies was founded as a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki in 2013 by researchers and pioneers in the field of cloud-based microscopy and pathology and experienced life science entrepreneurs. The Aiforia Platform brings together deep learning AI and high-performance cloud computing. Aiforia assists with the increased demand for image-based diagnostics by providing efficient and scalable solutions – enabling new discoveries and clinical support with highly accurate and consistent data. Aiforia is technologically driven establishment and keeps the capability of being image agnostic thus extending its solutions to multiple fields.